A New ERA in Scleroderma Interstitial Lung Disease and Renal Crisis: Rationale for Early Use of Endothelin Receptor Antagonists

被引：0
|
作者：
Sunseri, M. [1 ]
Gershner, K. [1 ]
Gunther, I. [1 ]
Brosnahan, S. [1 ]
机构：
[1] NYU, Langone Med Ctr, New York, NY USA
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2019年 / 199卷
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
A1523
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Targeting the endothelin axis in scleroderma renal crisis: rationale and feasibility
    Penn, H.
    Quillinan, N.
    Khan, K.
    Chakravarty, K.
    Ong, V. H.
    Burns, A.
    Denton, C. P.
    QJM-AN INTERNATIONAL JOURNAL OF MEDICINE, 2013, 106 (09) : 839 - 848
  • [2] A New Era in the Treatment of Scleroderma-associated Interstitial Lung Disease?
    Launay, David
    JOURNAL OF RHEUMATOLOGY, 2016, 43 (09) : 1619 - 1621
  • [3] Role of endothelin and endothelin receptor antagonists in renal disease
    Neuhofer, W.
    Pittrow, D.
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2006, 36 : 78 - 88
  • [4] Endothelin Receptor Antagonism-Based Treatment for Scleroderma Renal Crisis
    Izzedine, Hassane
    Rouvier, Philippe
    Deray, Gilbert
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2013, 62 (02) : 394 - 395
  • [5] New developments in scleroderma interstitial lung disease
    Highland, KB
    Silver, RM
    CURRENT OPINION IN RHEUMATOLOGY, 2005, 17 (06) : 737 - 745
  • [6] Endothelin Receptor Antagonists: New Hope for Renal Protection?
    Sheldon Tobe
    Donald E. Kohan
    Ranjit Singarayer
    Current Hypertension Reports, 2015, 17
  • [7] Endothelin Receptor Antagonists: New Hope for Renal Protection?
    Tobe, Sheldon
    Kohan, Donald E.
    Singarayer, Ranjit
    CURRENT HYPERTENSION REPORTS, 2015, 17 (07)
  • [8] NOVEL RECEPTOR ANTAGONISTS WELCOME A NEW ERA IN ENDOTHELIN BIOLOGY
    DOUGLAS, SA
    MEEK, TD
    OHLSTEIN, EH
    TRENDS IN PHARMACOLOGICAL SCIENCES, 1994, 15 (09) : 313 - 316
  • [9] Systemic sclerosis with interstitial lung disease and renal crisis
    Hellmich, B
    Schnabel, A
    Gross, WL
    INTERNIST, 1998, 39 (10): : 1062 - 1068
  • [10] The rationale for targeting the JAK/STAT pathway in scleroderma-associated interstitial lung disease
    Talotta, Rossella
    IMMUNOTHERAPY, 2021, 13 (03) : 241 - 256
12345